Fluidigm Corp
Change company Symbol lookup
Select an option...
FLDM Fluidigm Corp
ZN Zion Oil and Gas Inc
EBTC Enterprise Bancorp Inc
FSLY Fastly Inc
BNR Burning Rock Biotech Ltd
FCNKX Fidelity® Contrafund® Fund Class K
CAT Caterpillar Inc
POAGX PRIMECAP Odyssey Aggressive Growth Fund
VFIFX Vanguard Target Retirement 2050 Fund Investor Shares
CMCSA Comcast Corp
Go

Health Care : Life Sciences Tools & Services | Small Cap Blend
Company profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

Closing Price
$7.95
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
8,395,026
0

Display:

Providers:

UpdateCancel
6 providers
August 06, 2020
Fluidigm Announces Second Quarter 2020 Financial Results

Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass Cytometry Technology and Maxpar Direct Immune Profiling...(Globe Newswire)

August 04, 2020
Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis

Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a distribution agreement with De Novo Software(TM) to provide customers with access...(Globe Newswire)

July 31, 2020
Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced execution of a letter contract with the National Institutes of Health, National...(Globe Newswire)

July 20, 2020
GnomeDX Files for FDA Emergency Use Authorization for Rapid Turnaround Real-Time RT-PCR COVID-19 Test Utilizing the Fluidigm Biomark HD Platform

Test Intended to Expand Availability of COVID-19 Screening Resources in Central Ohio Workflow with Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Increasing Number of Labs Adopting the Fluidigm High-Throughput Testing Model (Globe Newswire)

July 06, 2020
Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report second quarter 2020 financial results on Thursday, August 6...(Globe Newswire)

June 29, 2020
Multi-Site Study of COVID-19 Patients Utilizing Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay

Tracking the Immune Response of Patients Hospitalized with COVID-19 in 10 Research Sites Across the United States Study May Inform Recommendations for COVID-19 Care, New Strategies for Treatments Fluidigm Corporation (Nasdaq:FLDM), an innovative...(Globe Newswire)

June 24, 2020
Integrated Genetics Lab Services Conducting COVID-19 Testing in Spain Utilizing Fluidigm Biomark HD Platform

iGLS Among Labs Chosen by Spanish Health Authorities to Expand SARS-CoV-2 Screening End-to-End Workflow from Extraction through Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Screening of Critical Populations Under Way, Capacity...(Globe Newswire)

June 17, 2020
New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System

Fluidigm to Be Exclusive Distributor for Bethyl Antibodies for Use with Imaging Mass Cytometry Providing Researchers with Expanded Capabilities in Interrogating the Tissue Microenvironment Fluidigm Corporation (Nasdaq:FLDM), an innovative...(Globe Newswire)

June 15, 2020
Thinking about buying stock in Fluidigm Corp, Xenetic Biosciences, Delta Air Lines, Occidental Petroleum Corp, or FuelCell Energy?

InvestorsObserver issues critical PriceWatch Alerts for FLDM, XBIO, DAL, OXY, and FCEL. https://mma.prnewswire.com/media/1086590/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

June 12, 2020
Fluidigm Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19

Extraction-Free, Real-Time PCR Workflow with Capacity of Up to 6,000 Tests per Day Easy-to-Administer Saliva Test Would Eliminate Need for Invasive Nasopharyngeal Swab High-Throughput Assay Developed in Collaboration with Washington University...(Globe Newswire)

May 19, 2020
University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that researchers at the University of Paris have utilized mass cytometry to identify...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.